Use of calcitonin to prevent complex regional pain syndrome type I in severe hemiplegic patients after stroke.
OBJECTIVE
To evaluate the effects of calcitonin in preventing complex regional pain syndrome type I (CRPS) in patients with severe hemiplegia following stroke.


METHODS
In this observer-blinded, controlled study comparison with historical controls between April 2003 and May 2004, subjects comprised consecutive patients with post-stroke hemiplegia admitted between June 2004 and September 2005, with any upper limb or finger graded as Brunnstrom stage (BrST) III or below. One group was administered intramuscular injection of 20 units of elcatonin (EL) (Asu(1-7) eel calcitonin) weekly from immediately after admission to discharge, together with rehabilitation therapy. The control group received rehabilitation therapy alone. Patients were observed during the in-hospital rehabilitation period. The main outcome measure was onset of CRPS.


RESULTS
Incidence of CRPS in all patients with post-stroke hemiplegia during the control period was about 8.2%, similar to recent studies. Limited to serious hemiplegic patients graded as BrST III or below, incidence of CRPS was significantly lower in the EL group (12.5%) than in controls (57.1%). No significant differences in patient background were seen between groups. CRPS was completely prevented when EL injection was started <or=4 weeks after stroke, but prophylactic effects were weak when EL was started >6 weeks after stroke.


CONCLUSIONS
Intramuscular calcitonin appears to suppress onset of CRPS after stroke, particularly when started early after stroke.
Matayoshi
Satoru
S
Department of Rehabilitation and Physical Medicine, Faculty of Medicine, Kagoshima University, Makizono-cho, Kagoshima, Japan.
Shimodozono
Megumi
M
Hirata
Yoshifumi
Y
Ueda
Toshie
T
Horio
Shinya
S
Kawahira
Kazumi
K
D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006429:Hemiplegia / Q000150:complications* / Q000209:etiology / Q000534:rehabilitation; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular; D008297:Male; D012019:Reflex Sympathetic Dystrophy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D018709:Statistics, Nonparametric; D020521:Stroke / Q000150:complications*; D000071939:Stroke Rehabilitation; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D002116:Calcitonin